S&P 500 slips, but losses kept in check as Nvidia climbs ahead of results
CAMBRIDGE, MA—Attar Eyal C., the Chief Medical (TASE:PMCN) Officer of Vor Biopharma Inc. (NASDAQ:VOR), recently sold shares of the company’s common stock, according to a filing with the Securities and Exchange Commission. The transaction, which occurred on February 10, involved the sale of 2,554 shares at a weighted average price of $1.37 per share, totaling approximately $3,498. The sale comes as VOR’s stock has experienced significant volatility, showing a -9% return over the past week but gaining over 62% in the last six months, according to InvestingPro data.
The sale was conducted under a Rule 10b5-1 trading plan, which allows company insiders to set up a predetermined plan to sell stock, helping to avoid concerns about insider trading. Following this transaction, Attar Eyal C. retains ownership of 128,852 shares of Vor Biopharma. The company maintains a strong liquidity position with a current ratio of 4.69, though InvestingPro analysis indicates it’s quickly burning through cash.
Vor Biopharma, headquartered in Cambridge, Massachusetts, focuses on developing innovative therapies for cancer treatment. The company continues to advance its pipeline in the life sciences sector. While currently showing Fair Value indicators, investors can access 10+ additional InvestingPro Tips and comprehensive analysis through the InvestingPro platform’s detailed research reports.
In other recent news, Vor Biopharma Inc., a biotechnology firm, has made significant changes to the exercise prices of certain stock options. The company’s board of directors approved a reduction of the exercise prices of outstanding stock options for continuing employees to $1.34 per share. This repricing affects options granted under the company’s 2015, 2021, and 2023 incentive plans that had exercise prices above $1.34.
In addition, Vor Biopharma has announced the appointment of Erez Kalir to its Board of Directors. Kalir’s addition to the board is part of Vor Bio’s ongoing efforts to strengthen its leadership as it advances its clinical programs.
Furthermore, Vor Biopharma has secured a private investment in public equity (PIPE) deal expected to yield approximately $55.6 million in gross proceeds. The financing is anticipated to close on December 30, 2024, contingent upon customary closing conditions.
Finally, Vor Biopharma plans to release updated clinical data from its Phase 1/2 VBP301 trial of VCAR33 in the first half of 2025. In the second half of the same year, Vor plans to share updated data from the Phase 1/2a VBP101 trial of trem-cel in combination with Mylotarg. These are the recent developments at Vor Biopharma.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.